Prostate Cancer Reports
54

Volume 5 Supplement 8
August 2017



Home > Prostate Cancer Reports > Volume 5, Year 2017 > Supplement 8, August


CONTENTS



DIAGNOSIS AND EVALUATION
EPIDEMIOLOGY, RISK FACTORS AND PREVENTION
ETIOLOGY, PATHOGENESIS AND PATHOLOGY
FOLLOW-UP AND QUALITY OF LIFE
OVERALL MANAGEMENT
PROGNOSIS
TREATMENT





DIAGNOSIS AND EVALUATION



Fütterer JJ.
Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer.
Korean J Radiol. 2017 Jul-Aug;18(4):597-606. doi: 10.3348/kjr.2017.18.4.597. Epub 2017 May 19.
Source | Abstract | Full text | Similar articles




Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ.
The influence of statin medications on prostate-specific antigen levels.
J Natl Cancer Inst. 2008 Nov 5;100(21):1511-8. doi: 10.1093/jnci/djn362
Source | Abstract | Full text | Similar articles




Kaipia A, Riikonen J.
Contemporary and past challenges of prostate cancer diagnostics.
Scand J Urol. 2017 Jun;51(3):193-201. doi: 10.1080/21681805.2017.1329902. Online 2017 Jun 28.
Source | Abstract | Full text | Similar articles




Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner M, Katayama S, Mier W, Iagaru AH, Herfarth K, Haberkorn U, Debus J, Giesel FL.
68Ga-PSMA11-PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters.
J Nucl Med. 2017 Jun 15. pii: jnumed.117.190314. doi: 10.2967/jnumed.117.190314. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Prostate. 2017 Aug;77(11):1205-1212. doi: 10.1002/pros.23379. Epub 2017 Jun 26.
Source | Abstract | Full text | Similar articles




Öbek C, Doğanca T, Demirci E, Ocak M, Kural AR, Yıldırım A, Yücetaş U, Demirdağ Ç, Erdoğan SM, Kabasakal L; Members of Urooncology Association, Turkey.
The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer.
Eur J Nucl Med Mol Imaging. 2017 Jun 18. doi: 10.1007/s00259-017-3752-y. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





EPIDEMIOLOGY, RISK FACTORS AND PREVENTION



Downer MK, Stampfer MJ, Cooperberg MR.
Declining Incidence Rates of Prostate Cancer in the United States: Is This Good News or Not?
JAMA Oncol. 2017 May 11. doi: 10.1001/jamaoncol.2017.0470. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Hu JC, Nguyen P, Mao J, Halpern J, Shoag J, Wright JD, Sedrakyan A.
Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States.
JAMA Oncol. 2017 May 1;3(5):705-707. doi: 10.1001/jamaoncol.2016.5465.
Source | Abstract | Full text | Similar articles




Jemal A, Ma J, Siegel R, Fedewa S, Brawley O, Ward EM.
Prostate Cancer Incidence Rates 2 Years After the US Preventive Services Task Force Recommendations Against Screening.
JAMA Oncol. 2016 Dec 1;2(12):1657-1660. doi: 10.1001/jamaoncol.2016.2667.
Source | Abstract | Full text | Similar articles




Penson DF.
Re: Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States.
J Urol. 2017 Jul;198(1):104-105. doi: 10.1016/j.juro.2017.04.041. Epub 2017 Apr 12.
Source | Abstract | Full text | Similar articles





ETIOLOGY, PATHOGENESIS AND PATHOLOGY



Adamowicz J, Pakravan K, Bakhshinejad B, Drewa T, Babashah S.
Prostate cancer stem cells: from theory to practice.
Scand J Urol. 2017 Apr;51(2):95-106. doi: 10.1080/21681805.2017.1283360. Epub 2017 Feb 7.
Source | Abstract | Full text | Similar articles





FOLLOW-UP AND QUALITY OF LIFE



Albaugh JA, Sufrin N, Lapin BR, Petkewicz J, Tenfelde S.
Life after prostate cancer treatment: a mixed methods study of the experiences of men with sexual dysfunction and their partners.
BMC Urol. 2017 Jun 15;17(1):45. doi: 10.1186/s12894-017-0231-5.
Source | Abstract | Full text | Similar articles




Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA.
Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.
Am Health Drug Benefits. 2017 May;10(3):143-153.
Source | Abstract | Full text | Similar articles





OVERALL MANAGEMENT



Weiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SE.
Contemporary management of men with high-risk localized prostate cancer in the United States.
Prostate Cancer Prostatic Dis. 2017 Jun 20. doi: 10.1038/pcan.2017.5. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





PROGNOSIS



Campbell JM, Raymond E, O'Callaghan ME, Vincent AD, Beckmann KR, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti KL.
Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity.
Clin Genitourin Cancer. 2017 Jun 8. pii: S1558-7673(17)30167-2. doi: 10.1016/j.clgc.2017.06.001. Epub 2017 Jun 7.
Source | Abstract | Full text | Similar articles




Nordström T, Clements M, Karlsson R, Adolfsson J, Grönberg H.
The risk of prostate cancer for men on aspirin, statin or antidiabetic medications.
Eur J Cancer. 2015 Apr;51(6):725-33. doi: 10.1016/j.ejca.2015.02.003. Epub 2015 Feb 23.
Source | Abstract | Full text | Similar articles




Stopsack KH, Greenberg AJ, Mucci LA.
Common medications and prostate cancer mortality: a review.
World J Urol. 2017 Jun;35(6):875-882. doi: 10.1007/s00345-016-1912-5. Epub 2016 Aug 4.
Source | Abstract | Full text | Similar articles




Vesely S, Jarolim L, Schmidt M, Do Carmo Silva J, Duskova K, Babjuk M.
Stratification model based on early postprostatectomy prostate-specific antigen kinetics may help to reduce the risk of overtreatment in candidates for adjuvant radiotherapy.
Scand J Urol. 2017 Apr;51(2):114-119. doi: 10.1080/21681805.2017.1292545. Epub 2017 Feb 24.
Source | Abstract | Full text | Similar articles




Yashi M, Nukui A, Tokura Y, Takei K, Suzuki I, Sakamoto K, Yuki H, Kambara T, Betsunoh H, Abe H, Fukabori Y, Nakazato Y, Kaji Y, Kamai T.
Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
BMC Urol. 2017 Jun 23;17(1):47. doi: 10.1186/s12894-017-0238-y.
Source | Abstract | Full text | Similar articles




Zareba P, Eastham J, Scardino PT, Touijer K.
Contemporary patterns of care and outcomes of men found to have lymph node metastases at the time of radical prostatectomy.
J Urol. 2017 Jun 15. pii: S0022-5347(17)74858-6. doi: 10.1016/j.juro.2017.06.062. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





TREATMENT



Chua B, Min M, Wood M, Edwards S, Hoffmann M, Greenham S, Kovendy A, McKay MJ, Shakespeare TP.
Implementation of an image guided intensity-modulated protocol for post-prostatectomy radiotherapy: planning data and acute toxicity outcomes.
J Med Imaging Radiat Oncol. 2013 Aug;57(4):482-9. doi: 10.1111/1754-9485.12043. Epub 2013 Feb 27.
Source | Abstract | Full text | Similar articles




Delouya G, Lambert C, Bahary JP, Beauchemin MC, Barkati M, Ménard C, Taussky D.
Comparison of external beam radiotherapy versus permanent seed brachytherapy as monotherapy for intermediate-risk prostate cancer - a single center Canadian experience.
Can J Urol. 2017 Jun;24(3):8822-8826.
Source | Abstract | Full text | Similar articles




Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M.
177Lu-PSMA radioligand therapy for prostate cancer.
J Nucl Med. 2017 Jun 29. pii: jnumed.117.191023. doi: 10.2967/jnumed.117.191023. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Kibel AS.
Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure.
J Urol. 2017 Jun 16. pii: S0022-5347(17)74842-2. doi: 10.1016/j.juro.2017.06.055. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Mannas MP, Chedgy ECP, Black PC.
You Pays Your Money, You Takes Your Choice: Functional Outcomes Following Curative Treatment for Clinically Localized Prostate Cancer Commentary on: Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-reported Outcomes After 3 Years.
Urology. 2017 Jun 15. pii: S0090-4295(17)30625-8. doi: 10.1016/j.urology.2017.06.011. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Marenghi C, Alvisi MF, Palorini F, Avuzzi B, Badenchini F, Bedini N, Bellardita L, Biasoni D, Bosetti D, Casale A, Catanzaro M, Colecchia M, De Luca L, Donegani S, Dordoni P, Lanocita R, Maffezzini M, Magnani T, Menichetti J, Messina A, Morlino S, Paolini B, Rancati T, Stagni S, Tesone A, Torelli T, Tulli Baldoin E, Vaiani M, Villa S, Villa S, Zaffaroni N, Nicolai N, Salvioni R, Valdagni R.
Eleven-year management of prostate cancer patients on active surveillance: what have we learned?
Tumori. 2017 Jun 14:0. doi: 10.5301/tj.5000649. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Mazzei MM, Sindoni A, Santacaterina A, Platania A, Marino L, Umina V, Girlando A, Ricottone N, D'Agostino A, Marletta F, Tamburo M, Acquaviva G, Spatola C, Privitera G, Frosina P, Garufi G, Bonanno S, Rosso A, Barone V, Corallo A, Sansotta G, Delia P, Donato V, Lopes S, Pisana M, Runco R, Risoleti E, Arcudi A, Rifatto C, Arena G, Potami A, Messina G, Parisi S, Marletta D, Pontoriero A, Iatì G, Pergolizzi S.
Radiation therapy utilisation in patients with bone metastases secondary to prostate cancer: A multicenter study.
Eur J Cancer Care (Engl). 2017 Jul;26(4). doi: 10.1111/ecc.12681. First published: 28 June 2017
Source | Abstract | Full text | Similar articles




Noguchi M, Koga N, Igawa T, Itoh K.
Clinical development of immunotherapy for prostate cancer.
Int J Urol. 2017 Jun 21. doi: 10.1111/iju.13397. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Roth S.
[Radiation with additional antiandrogen therapy in recurrent prostate cancer].
Strahlenther Onkol. 2017 Aug;193(8):679-681. doi: 10.1007/s00066-017-1171-4. German. First Online:
26 June 2017
Source | Abstract | Full text | Similar articles




Traboulsi SL, Saad F.
The role of bone-targeted therapies for prostate cancer in 2017.
Curr Opin Support Palliat Care. 2017 Jul 20. doi: 10.1097/SPC.0000000000000280. [Epub ahead of print]
Source | Abstract | Full text | Similar articles